Federal buget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC (S.3295); the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, and international health. Legislation includes H. Con. Res. 34, establishing the budget for the US Government for FY 2012; and issues relating to consolidation of categorized cancer prevention programs of the Centers for Disease Control and Prevention.
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for LifeAct of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, icluding: S. 868 and H.R. 1683, the State Flexibility Act ( MOE). Issues realting to inclusion of palliative care as a bundled service within CMS "value-based purcahsing".
Duration: January 1, 2008
to
August 31, 2012
General Issues: Budget/Appropriations , Health Issues , Medicare/Medicaid , Tobacco , Taxation/Internal Revenue Code
Spending: about $3,340,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2012
AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. in-house lobbying effort was terminated on Oct. 19, 2012
Original Filing: 300513297.xml
Lobbying Issues
Federal buget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC (S.3295); the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, and international health. Legislation includes H. Con. Res. 34, establishing the budget for the US Government for FY 2012; and issues relating to consolidation of categorized cancer prevention programs of the Centers for Disease Control and Prevention.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for LifeAct of 2010; H.R. 2941 and S. 3493; the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoing national shortage of cancer drugs, amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, icluding: S. 868 and H.R. 1683, the State Flexibility Act ( MOE). Issues realting to inclusion of palliative care as a bundled service within CMS "value-based purcahsing".
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on July 20, 2012.
Original Filing: 300498800.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC (S.3295); the Prevention & Public Helath Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, and international health. Legislation includes H. Con. Red. 34, establishing the budget for the US Government for FY 2012; and issues relating to consolidation of categorized cancer prevention programs of the Centers for Disease Control and Prevention.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to health disparities, health care reform, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912 Colorectal Cancer Prevention, Early Detection & Treatment Act; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493; H.R. 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; S. 1064, The Sun Act; S. 965, the Family Act; H.R. 2954, Health Equity and Accountability Act of 2011; and H.R. 2077, the MLR Repeal Act; H.R. 2245and S.296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, S. 3187, the FDA Safety and Innovation Act and the House Companion legislation, and issues relating to the ongoig the national shortage of cancer drugs. Amendment relating to S. 1813, the Moving Ahead for Progress in the 21st Century Act, and H.R. 4274, reauthorization of the Best Pharmaceutials for Children Act and the Pediatric Research Equity Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, including: S. 868 and H.R. 1683, the State Flexibility Act (MOE). Issues relating to inclusion of palliative care as a bundled service with CMS "value-based purchasing".
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environmernts including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations form the Executive in Need of Scrutiny Act of 2011; (4) Framework Convention on Tobacco Control (FCTC): and (5) issues relating to NIH reorganization. Legislation includes H.R. 3186 and S. 1706, Smuggled Tobacco Prevention Act; H.R. 3382, Smoke-Free Federal Building Act; S. 1403, IDEA Full Funding Act; and H.R. 65: Candy Tobacco Tax Parity Act of 2011. Issues related to cigar regulation on H.R. 5973.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on April 19, 2012.
Original Filing: 300468134.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, and international health; and matters under consideration by the Joint Select Committee on Deficit Reduction. Legislation includes H. Con. Res. 34, establishing the budget for the US Government for FY2012; S. 1599, legislation including draft House text of legislation making appropriations for L-HHS FY 12; H.R. 2055 and S. 3671, Consolidated Appropriations Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S. 494 and H.R. 912, Colorectal Cancer Prevention, Early Detection & treatment Act; H.R. 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention and Public Health Fund; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R.2941 and S. 3493; HR 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; HR 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010; S. 1064, the Sun Act; S. 965, the Family Act; HR 2954, Health Equity and Accountability Act of 2011; and HR 2077, the MLR Repeal Act; H.R. 2245 and S. 296 Preserving Access to Life-Saving Medications Act, issues related to the reauthorization of the prescription drug user fee, and issues relating to the ongoing national shortage of cancer drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs within Medicaid, including S. 868 and H.R. 1683, the State Flexibility Act (MOE); and matters under consideration by the Joint Select Committee on Deficit Reduction.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations from the Executive in Need of SecurityAct of 2011; (4) Framework Convention on Tobacco Control (FCTC); and (5) issues relating to NIH reorganization. Legislation includes H.R. 3186 and S. 1706, Smuggled Tobacco Prevention Act; H.R. 3382, Smoke-Free Federal Building Act; S. 1403, IDEA Full Funding Act; And H.R. 65: Candy Tobacco Tax Parity Act of 2011.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on Jan. 20, 2012.
Original Filing: 300451541.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for NIH, NCI, CDC; the Prevention & Public Health Fund; the Affordable Care Act provisions; programs for breast and cervical cancer, colorectal cancer, tobacco regulation and cessation, patient navigators, and international health; and matters under consideration by the Joint Select Committee on Deficit Reduction. Legislation includes H. Con. Res. 34, establishing the budget for the US Government for FY 2012; S. 1599, draft Houst text of legislation making appropriations for L-HHS FY 12; and S. 365, the Budget Control Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: S 494 and HR 912, Colorectal Cancer Prevention, Early Detection & Treatment Act; HR 1213, Repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; HR 1217, Repeal Prevention and Public Health Fund; HR 1740 and HR 5560, the Quality Cancer Care for Life Act of 2010; HR 2941 and S 3493; HR 3974, Viral Hepatatis and Liver Cancer Control and Prevention Act of 2009; HR 4662, the Lymphedema Diagnosis and Treatment Cost Savings Act of 2010; the implementation of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010; S 1064, the Sun Act; S 965, the Family Act; HR 2954, Health Equity and Accountability Act of 2011; and HR 2077, the MLR Repeal Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010, and tobacco cessation programs with Medicaid, including: S 717 and H.R. 6224; H Con. Res. 34, establishing a budget for the US Government for FY 12; S. 868 and H.R. 1683, the State Flexibility Act (MOE); and matters under construction by the Joint Select Committee on Deficit Reduction.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including: (1) implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31): (2) cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010; (3) legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations from the Executive in Need of ScrutinyAct of 2011; (4) Framework Convention on Tobacco Control (FCTC); and (5) issues relating to NIH reorganization.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on Oct. 20, 2011.
Original Filing: 300426242.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for the Prevention & Public Health Fund, the Affordable Care Act provisions, breast and crevical programs, colorectal cancer programs, tobacco regulation & cessation programs, patient navigator programs, and international health programs, including S. 3686, the Senate Labor-HHS appropriations for FY11, each of the continuing resolutions making appropriations for FY11, H.R. 1473 making remaining appro-priations for FY11, H. Con. Res. 34, establishing the budget for the U.S. Government for FY 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R. 1189, Colorectal Cancer Prevention, Early Detection & Treatment Act; S. 494 and H.R. 912; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention & Public Health Fund; S. 488, the Access to Cancer Clinical Trials Act of 2009; H.R. 1740 and H.R. 5660, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493, Johanna's Law reauthorization; H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R. 2366, the Cancer Drug Coverage Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Saving Act of 2010; the implementation of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010; and child nutrition reauthorization bills(H.R. 5504, Improving Nutrition for America's Children Act, and S. 3307, Healthy, Hunger-Free Kids Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010. Issues relating to tobacco cessation programs within Medicaid, including S. 717 and H.R. 6224, H. Con. Res. 34, establishing a budget for the U.S. Government for FY12.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokefree environments, including implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), and cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010. Legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations from the Executive in Need of Scrutiny and Frame-work Convention on Tobacco Control (FCTC), and issues relating to NIH reorganization.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on July 20, 2011.
Original Filing: 300401642.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for the Prevention & Public Health Fund, the Affordable Care Act provisions, breast and cervical programs, colorectal cancer programs, tobacco regulation & cessation programs, patient navigator programs, and international health programs, including S. 3686, the Senate Labor-HHS appropriations for FY11, each of the continuing resolutions making appropriations for FY11, H.R. 1473 making remaining appropri-ations for FY11, H. Con. Res. 34, establishing the budget for the U.S. Government for FY 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R. 1189, Colorectal Cancer Prevention, Early Detection & Treatment Act; S. 494 and H.R. 912; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, repeal Prevention & Public Health Fund; S. 488, the Access to Cancer Clinical Trials Act of 2009; H.R. 1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493, Johanna's Law reauthorization; H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R. 2366, the Cancer Drug Coverage Act of 2009; H.R. 4662, the Lymphedema Diagnosis and Treatment Cost Saving Act of 2010; the implemenatation of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010; and child nutrition reauthorization bills (H.R. 5504, Improving Nutrition for America's Children Act, and S. 3307, Healthy, Hunger-Free Kids Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to implementation of changes to Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010. Issues relating to tobacco cessation programs within Medicaid, including S. 717 and H.R. 6224, H. Con. Res. 34, establishing a budget for the U.S. Government for FY12.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco sales to minors, tobacco taxes, product regulation, and smokingfree environments, including implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), and cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010, legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations from the Executive in Need of Scrutiny and Frame-work Convention on Tobacco Control (FCTC), and issues relating to NIH reorganization.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on April 19, 2011.
Original Filing: 300372819.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for the Prevention & Public Health Fund, the Affordable Care Act provisions, breast and cervical programs, colorectal cancer programs, tobacco regulation & cessation programs, patient navaigator programs, and international health programs, including S. 3686, the Senate Labor-HHS appropriations for FY11, each of the continuing resolutions making appropriations for FY11, H.R. 1473 making remaining appropri-ations for FY11, H. Con. Res. 34, establishing the budget for the U.S. Government for FY 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation; H.R. 1189, Colorectal Cancer Prevention, Early Detection & Treatment Act; S. 494 and H.R. 912; H.R. 1213, repeal mandatory funding provided to states in PPACA to establish American Health Benefit Exchanges; H.R. 1217, Repeal Prevention & Public Health Fund; S. 488, The Access to Cancer Clinical Trials Act of 2009; H.R.1740 and H.R. 5560, the Quality Cancer Care for Life Act of 2010; H.R. 2941 and S. 3493, Johanna's Law reauthorization; H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; H.R. 2366, the Cancer Drug Coverage Act of 2009; H.R. 4662, The Lymphedema Diagnosis and Treatment Cost Saving Act of 2010; and child nutrition reauthorization bills (H.R. 5504, Improving Nutrition for America's Children Act, and S. 3307, Healthy, Hunger-Free Kids Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relatred to implementation of changes of Medicare and Medicaid, pursuant to P.L. 111-148, the Patient Protection and Affordable Care Act of 2010. Issues relating to tobacco cessation programs within Medicaid, including S. 717 and H.R. 6224, H. Con. Res. 34, establishing a budget for the U.S. Government for FY12.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Act of 2011 Issues related to smoking cessation, tobacco sales to minors, tobacco taxes, product regulaiton, and smokefree environments, including implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), and cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010, legislation regarding Congressional review/approval of regulations, including H.R. 10, the Regulations from the Executive in Need of Scrutinyand Framework Convention on Tobacco Control (FCTC), and relating to NIH reorganization
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on Jan. 19, 2011.
Original Filing: 300346045.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for breast and cervical programs, colorectal cancer programs, and patient navigator programs, including S. 3686, the Senate Labor-HHS appropriations for FY 11, and the comparable unamed House Bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health disparities, health care reform, quality of life, federal helath care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R. 1189 Colorectal Cancer Early Detection, Prevention and Treatment Act; S. 717, and H.R. 6224, The 21st Century Cancer Alert Act; proposed Senate national cancer program authorizing legislation; S. 488, the Access to Cancer Trials Act of 2009; H.R. 1740 and H.R. 5560, the Quality Cancer Care of Life Act of 2010 and the implementation of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health care reform, Medicare and Medicaid, coverage of cancer related services and prevention measures, including H.R. 2291, the Medicare Early Detection of Cancer Promotion Act. Issues relating to implementation of Medicare & Medicaid related provisions enacted as Part of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010. Issues relating to tobacco cessation progrmas within Medicaid, including S. 717 and H.R. 6224, the 21st Century Cancer Alert Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco taxes and product regulation, including implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), H.R. 1850, the Quit Smoking for Life Act, and related cessation legislation, and cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on Oct. 20, 2010.
Original Filing: 300325592.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for breast and cervical programs, colorectal cancer programs, and patient navigator programs, including S. 3686, the Labor-HHS appropriations for FY 11, and the comparable unnamed House Bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health disparities, health care reform, quality of life, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R. 1189 Colorectal Cancer Early Detection, Prevention and Treatment Act; S. 717, and H.R. 6224, The 21st Century Cancer Alert Act; proposed Senate national cancer program authorizing legislation; S. 488, the Access to Cancer Clinical Trials Act of 2009; H.R. 1740 and H.R. 5560, the Quality Cancer Care of Life Act of 2010 and the implementation of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health care reform, Medicare and Medicaid, coverage of cancer-related services and prevention measures, including H.R, 2291, the Medicare Early Detection of Cancer Promotion Act. Issues relating to implementation of Medicare & Medical realted provisions enacted as part of P.L. 111-148, the Patient Protection and Affordable Care Act of 2010. Issues relating to tobacco cessation programs within Medicaid, including S. 717 and H.R. 6224, the 21st Century Cancer ALERT Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco taxes and product regulation, including implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), H.R. 1850, the Quit Smoking for Life Act, and related cessation legislation, and cessation and prevention programs authorized as part of P.L. 111-148, the Patient Protection & Affordable Care Act of 2010.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on July 27, 2010.
Original Filing: 300305187.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for breast cancer and cervical programs, colorectal cancer programs, and patient navigator programs, H.R. 3293 Labor - HHS Appropriations for FY10
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health disparities, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R. 1189 Colorectal Cancer Early Detection, Prevention and Treatment Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid, coverage of cancer related services and prevention measures, including HR 2291, the Medicare Early Detection of Cancer Promotion Act. Issues relating to Medicare & Medicaid in the House & Senate health care reform bills in HR 3590 & 3962. Issues relating to tobascco cessation programs within Medicaid, including D 717 the 21st Century Cancer Alert Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco taxes and product regulation, including H.R. 1256, Family Smoking Prevention and Tobacco Control Act, and HR 1850 the Quit Smoking for Life Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on April 19, 2010.
Original Filing: 300268944.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for breast and cervical programs, colorectal cancer programs, and patient navigator programs, H.R. 3293 Labor - HHS Appropriations for FY10
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health disparities, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R. 1189 Colorectal Cancer Early Detection, Prevention and Tratment Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid, coverage of cancer-related services and prevention measures, including HR 2291, the Medicare Early Detection of Cancer Promotion Act. Issues relating to Medicare & Medicaid in the House & Senate health care reform bills in HR 3590 & 3962. Issues relating to tobacco cessation programs within Medicaid, including S 717 the 21st Century Cancer Alert Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco taxes and product regulation, including H.R. 1256, Family Smoking Prevention and Tobacco Control Act, and HR 1850 the Quit Smoking for Life Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on Jan. 20, 2010.
Original Filing: 300247487.xml
Lobbying Issues
Federal budget and aprropriations for cancer research and programs, including federal appropriations for breast and crevical programs, colorectal cancer programs, and patient navigator programs. H.R. 3293 Labor - HHS Appropriations for FY10
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health disparities, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R. 1189 Colorectal Cancer Early Detection, Prevention and Treatment Act of 2009 H.R. 756 S 600 National Pain Care Policy Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid, coverage of cancer-related services and prevention measures, including HR 2291, the Medicare Early Detection of Cancer Promotion Act. Issues relating to Medicare & Medicaid in the House & Senate health care reform bills. Issues relating to tobacco cessation programs within Medicaid, including S 717 the 21st Center Cancer Alert Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relted to smoking cessation, tobacco taxes and product regulation, including H.R. 1256, Family Smoking Prevention and Tobacco Control Act, and tobacco tax aspects of H.R. 2, the SCHIP legislation
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on Oct. 20, 2009.
Original Filing: 300220234.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for breast and cervical programs, colorectal cancer programs, and patient navigator programs. HR 3293 Labor - HHS Appropriations for FY10
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health disparities, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: HR 1189 Colorectal Cancer Early Detection, Prevention and Treatment Act of 2009. HR 756 S 660 National Pain Care Policy Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid, coverage of cancer-related services and prevention measeures, including HR 2291, the Medicare Early Detection of Cancer Promotion Act. Issues relating to Medicare & Medicaid in the House & Senate health care reform bills. Issues relating to tobacco cessation programs within Medicaid, including S 717 the 21st Century Cancer Alert Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco taxes and product regulation, including HR 1256 Family Smoking Prevention and Tobacco Control Act, and tobacco tax aspects of HR 2 the SCHIP legislation
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on July 16, 2009.
Original Filing: 300181366.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for breast and cervical programs, colorectal cancer programs, and patient navigator programs, H. Con. Res. 85, House Budget resolution, and S. Con. Res. 13, Senate Budget Resolution, National Cancer Fund legislation, HR 1, The American Recovery and Reinvestment Act oof 2009, and H.R. 1105, Omnibus appropriations legislation for FY09, labor HHS Appropriations for FY10
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health disparities, federal health care programs, genetic information, cancer, nutrition, and wellness, including the following legislation: H.R. 1189 Colorectal Cancer Early Detection, Prevention and Treatment Act of 2009. H.R. 756 S 660 National Pain Care Policy Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to health care reform. Issues relating to tobacco cessation programs within Medicaid, including S 717 the 21st Center Cancr Alert Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco taxes and product regulation, including H.R. 1256, Family Smoking Prevention and Tobacco Control Act, and tobacco tax aspects of H.R. 2, the SCHIP legislation
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on April 20, 2009.
Original Filing: 300159693.xml
Lobbying Issues
FY 2009-2010 Federal Appropriations for cancer research and programs at the National Institutes of Health, National Cancer Institute, Centers for Disease Control, National Center on Minority Health and Health Disparities. FY 2009-2010 House and Senate Budget Resolutions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1189 Colorectal Cancer Early Detection, Prevention and Treatment Act of 2009
HR 756 S 660 National Pain Care Policy Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco taxes and product regulation, inculding HR 1256, Family Smoking Prevention and Tobacco Control Act
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on Jan. 16, 2009.
Original Filing: 300123035.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for breast and cervical programs and patient navigator programs. H. Con. Res. 312, House Budget Resolution, and S. Con. Res. 70, Senate Budget Resolution, Supplemental appropriations HR 2642, S. 3230 making FY 09 appropriations for Labor, Health & Human Services, and HR 6791, the National Cancer Fund Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1738 Colorectal Cancer Early Detection, Prevention and Treatment Act
H.H. 2994 National Pain Care Policy Act of 2007
S. 400 and H.R. 2851 Michelle's Law Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid, coverage of cancer-related services and prevention measures including H.R. 3042 Medicare Early Detection of Cancer Promotion Act, and S. 2499, H.R. 6331 and S. 3101 Medicare Improvements for Patients and Providers Act. Issues realting to health care reform.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco taxes and product regulation, including H.R. 1108/S. 625, Family Smoking Prevention and Tobacco Control Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on Oct. 20, 2008.
Original Filing: 300104741.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for breast and cervical programs and patient navigator programs, H. Con. Res. 312, House Budget Resolution, and S. Con. Res. 70, Senate Budget Resolution, Supplemental appropriations HR 2642, S 3230 making FY 09 appropriations for Labor, Health & Human Services, and HR 6791, the National Cancer Fund Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1738 Colorectal Cancer Early Detection, Prevention and Treatment Act
HR 2994 national pain Care policy Act of 2007
S 400 and HR 2851 Michelle's Law Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid, coverage of cancer-related services and prevention measures including HR 3042 Medicare Early Detection of Cancer Promotion Act, and S 2499, HR 6331 and S. 3101 Medicare Improvements for Patients and Providers Act. Issues relating to health care reform.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco taxes and product regulation, including HR 1108/S 625, Family Smoking prevention and Tobacco Control Act
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on July 21, 2008.
Original Filing: 300081811.xml
Lobbying Issues
Federal budget and appropriations for cancer research and programs, including federal appropriations for breast and cervical programs and patient navigation programs, H. Con. Res. 312, House Budget Resolution and S. Con. Res. 70, Senate Budget Resolution, Supplemental appropriations HR 2642, and House and Senate unnumbered appropriations bills for Labor, Health & Human Services
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1738 Colorectal Cancer Early Detection, Prevention and Treatment Act
HR 2994 National Pain Care Policy Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare and Medicaid, coverage of cancer-related services and prevention measures including HR 3042 Medicare Early Detection of Cancer Promotion Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to smoking cessation, tobacco taxes and product regulation, including HR 1108/S 625 Family Smoking Prevention and Tobacco Control Act
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION, INC. had in-house lobbyists. The report was filed on April 21, 2008.
Original Filing: 300054139.xml
Lobbying Issues
FY 2008-2009 Federal appropriations for cancer research and programs at the National Institutes of Health, National Cancer Institute, Centers for Disease Control, National Center on Minority Health and Health Disparities. FY 2008-2009 House and Senate Budget Resolutions
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1738 Colorectal Cancer Early Detection, Prevention and Treatment Act
HR 2994 National Pain Care Policy Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 3042 Medicare Early Detection of Cancer Promotion Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 1108/S 625 Family Smoking Prevention and Tobacco Control Act
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...